Shandong Lukang Pharmaceutical (600789.SH): Injection penicillin sodium obtained drug registration certificate.

Shandong Lukang Pharmaceutical (600789.SH) announced that the company has recently received the "Drug Registration Certificate" for sodium benzylpenicillin for injection issued by the National Medical Products Administration (Certificate number: 2026S00837, 2026S00838). The drug has been approved for registration. Sodium benzylpenicillin is a penicillinase-resistant penicillin that exerts bactericidal effects by inhibiting the biosynthesis of bacterial cell walls in actively proliferating penicillin-sensitive microorganisms. Resistance to penicillin may be due to the destruction of the beta-lactam ring by beta-lactamase, changes in the affinity of penicillin to its target, or a decrease in antibiotic concentration reaching the target area. Resistance to benzylpenicillin suggests resistance to other beta-lactam antibiotics, except for newly developed drugs that are still effective against methicillin-resistant Staphylococcus aureus.